LEUVEN, Belgium, April 14, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, notes the recent media speculation regarding its strategic review.
As announced on 24 February 2014, ThromboGenics is currently exploring strategic options for the Company, to allow it to realize the significant commercial potential of JETREA® in the US, and to fully exploit the Company's proven product development capabilities.
The strategic review is at a preliminary stage. The Company does not intend to comment further on market speculation unless and until it otherwise deems further disclosure is appropriate or required.Ends
|ThromboGenics Wouter Piepers, Global Head of Corporate Communications/ IR +32 16 75 13 10 / +32 478 33 56 32 firstname.lastname@example.org||Citigate Dewe Rogerson David Dible Tel: +44 20 7638 9571 email@example.com|